A biomimetic solution, albumin-doxorubicin molecular complex, targeting tumor and tumor-draining lymph nodes
Rui Guo1, Lanlan Zhong1, Sirui Ma1
1Key Laboratory of Drug-Targeting & Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drugs & Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610064, P. R. China. gongtao@scu.edu.cn.
Abstract:
Chemotherapy-induced immunologic cell death is haunted by the non-specific distribution of chemotherapeutic drugs and insignificant immune activation effects, which render efforts to inhibit the distant metastasis of tumors frustrated. Given the pivotal role that lymph nodes play in tumor metastasis, it is of vital importance whether the drug delivery to tumor-draining lymph nodes (TDLNs) succeeds. In the current study, we developed a doxorubicin-albumin complex (DOX-HSA) solution with the specific ability to simultaneously target the primary tumor and the TDLNs. DOX-HSA could effectively activate and amplify the immunogenic cell death (ICD) effect in both the tumor tissues and the TDLNs, resulting in increased release of damage-associated molecular patterns (DAMPs), which further promoted phagocytosis and maturation of dendritic cells (DCs), stimulated activation of CD8+T cells, and then significantly enhanced the therapeutic effects of doxorubicin on orthotopic 4T1 tumor-bearing model mice. Therefore, the DOX-HSA solution demonstrated a more prominent ability to control cancer cells and curb metastasis, as well as improved security by reducing cardiotoxicity and myelosuppression toxicity of doxorubicin itself. This DOX-HSA strengthened the synergistic anti-tumor effects based on the ICD effect in combination with traditional chemotherapy, thus providing promising prospects for clinical application.
Insights
A novel doxorubicin-albumin complex (DOX-HSA) effectively targets tumors and lymph nodes, enhancing immunogenic cell death (ICD) and reducing chemotherapy side effects for improved cancer treatment.
Area of Science:
- Oncology
- Immunology
- Nanomedicine
Background:
- Chemotherapy often suffers from non-specific drug distribution and weak immune activation, hindering the inhibition of distant tumor metastasis.
- Tumor-draining lymph nodes (TDLNs) are critical in tumor metastasis, making effective drug delivery to these sites essential for therapeutic success.
Purpose of the Study:
- To develop a doxorubicin-albumin complex (DOX-HSA) capable of simultaneously targeting primary tumors and TDLNs.
- To evaluate the efficacy of DOX-HSA in activating and amplifying immunogenic cell death (ICD) in both tumor tissues and TDLNs.
- To assess the therapeutic effects and safety profile of DOX-HSA in a preclinical cancer model.
Main Methods:
- Development of a doxorubicin-albumin complex (DOX-HSA) for targeted drug delivery.
- Evaluation of DOX-HSA's ability to induce immunogenic cell death (ICD) and release damage-associated molecular patterns (DAMPs).
- Assessment of dendritic cell (DC) maturation, CD8+ T cell activation, and anti-tumor efficacy in an orthotopic 4T1 tumor-bearing mouse model.
Main Results:
- DOX-HSA demonstrated simultaneous targeting of primary tumors and TDLNs, significantly enhancing ICD effects.
- Treatment with DOX-HSA led to increased DAMPs release, promoting DC maturation and CD8+ T cell activation.
- DOX-HSA exhibited superior anti-tumor activity and metastasis control compared to free doxorubicin, with reduced cardiotoxicity and myelosuppression.
Conclusions:
- The DOX-HSA complex offers a promising strategy for synergistic anti-tumor effects by combining chemotherapy with enhanced ICD.
- Targeted delivery to TDLNs via DOX-HSA improves therapeutic outcomes and reduces systemic toxicity.
- DOX-HSA presents a viable approach for clinical translation in cancer therapy, addressing limitations of conventional chemotherapy.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy